600645 Stock Overview
Primarily engages in the preparation and storage of cell detection tests in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 600645 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Vcanbio Cell & Gene Engineering Corp., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥20.32 |
| 52 Week High | CN¥24.08 |
| 52 Week Low | CN¥12.88 |
| Beta | 0.41 |
| 1 Month Change | 3.57% |
| 3 Month Change | 9.84% |
| 1 Year Change | 4.85% |
| 3 Year Change | -15.65% |
| 5 Year Change | 21.17% |
| Change since IPO | 679.52% |
Recent News & Updates
Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Popularity With Investors Is Under Threat From Overpricing
Sep 27
Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?
Aug 26Recent updates
Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Popularity With Investors Is Under Threat From Overpricing
Sep 27Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?
Aug 26Does Vcanbio Cell & Gene Engineering (SHSE:600645) Have A Healthy Balance Sheet?
May 24Vcanbio Cell & Gene Engineering's (SHSE:600645) Soft Earnings Are Actually Better Than They Appear
May 02Subdued Growth No Barrier To Vcanbio Cell & Gene Engineering Corp., Ltd's (SHSE:600645) Price
Apr 24Shareholder Returns
| 600645 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 2.7% | -1.9% | -1.2% |
| 1Y | 4.9% | -16.2% | 11.8% |
Return vs Industry: 600645 exceeded the CN Biotechs industry which returned -16.2% over the past year.
Return vs Market: 600645 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 600645 volatility | |
|---|---|
| 600645 Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 600645 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600645's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 2,209 | Hongqi Wang | www.vcanbio.com |
Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, primarily engages in the preparation and storage of cell detection tests in the People’s Republic of China. The company provides cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental sub totipotent stem cells, immune cells, adipose stem cells, and dental stem cells. It also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, genetic testing for drug safety guidance, disease genetic testing, and disease susceptibility testing for children and adults; and in vitro diagnostic raw materials, such as monoclonal antibodies and polyclonal antibody products.
Vcanbio Cell & Gene Engineering Corp., Ltd Fundamentals Summary
| 600645 fundamental statistics | |
|---|---|
| Market cap | CN¥9.82b |
| Earnings (TTM) | CN¥107.45m |
| Revenue (TTM) | CN¥1.59b |
86.2x
P/E Ratio5.8x
P/S RatioIs 600645 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600645 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.59b |
| Cost of Revenue | CN¥502.62m |
| Gross Profit | CN¥1.09b |
| Other Expenses | CN¥983.19m |
| Earnings | CN¥107.45m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 68.45% |
| Net Profit Margin | 6.74% |
| Debt/Equity Ratio | 1.1% |
How did 600645 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 08:45 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vcanbio Cell & Gene Engineering Corp., Ltd is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bin Wu | Founder Securities Co., Ltd. |
| Ye Hui Yang | Huatai Research |
| Ban Wang | Minsheng Securities Co. |